Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Chemokine Therapeutics has announced positive data following the successful completion of the Phase I/II clinical trial for CTCE-9908, the company's anti-cancer drug candidate.
Subscribe to our email newsletter
The primary objective of this Phase I/II clinical trial was to determine the tolerability and safety profile of repeated administration of CTCE-9908. The secondary objective was to evaluate early signs of efficacy such as tumor stabilization and reduction of tumor growth and spread.
The final results demonstrate that repeat dosing of CTCE-9908 is well tolerated with no dose limiting toxicity observed up to the maximum dose of 5.0mg/kg/day.
Results also showed encouraging signs of efficacy. A total of 20 patients received the targeted efficacious dose of 1-5mg/kg/day based on preclinical studies and were evaluable for tumor response. From this number, six patients (30%) had overall stable disease after one cycle (one month).
One patient with ovarian cancer had a significant reduction in the tumor marker CA125 with a correlating reduction in target tumor size after less than one cycle of treatment.
Walter Korz, president and CEO of Chemokine, said: “Based on the safety data of this trial we are now preparing to move forward with our Phase II cancer study.”